BrainStorm’s case for ALS approval relies on ‘grossly deficient’ data; What ever happened to biotech’s big comeback?

Taking stock of the drug industry, from the lab to the medicine chest

September 25, 2023 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Adobe STAT+ | BrainStorm's case for ALS approval relies on 'grossly deficient' data, FDA finds BrainStorm filed for approval over the FDA's protest, insisting NurOwn has demonstrated benefits for a subset of ALS patients. By Damian Garde STAT+ | What ever happened to biotech's big comeback? Biotech stocks have dramatically underperformed in 2023, dashing hopes that a sector-wide slump would be reversed. By Allison DeAngelis and Damian Garde STAT+ | Cancer drug shortages widen disparities between big systems and small Small clinics, with less ability to handle cisplatin and carboplatin shortages, have had to divert chemotherapy patients to bigger hospitals. By Angus Chen

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser